Sequence of treatments for adults with primary immune thrombocytopenia

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  George, James N ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR AGONIST; DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO; PREDNISONE; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTICLE; CLINICAL EFFECTIVENESS; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LUNG INFECTION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK ASSESSMENT; SERUM SICKNESS; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HEMORRHAGE; HUMANS; IMMUNOLOGIC FACTORS; MALE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, THROMBOPOIETIN; REMISSION INDUCTION; SPLENECTOMY;

EID: 84860008625     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23132     Document Type: Article

References (29)

1. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
2. Doan CA, Bouroncle BA, Wiseman BK. Idiopathic and secondary thrombocytopenic purpura: Clinical study and evaluation of 381 cases over a period of 28 years. Ann Int Med 1960; 53: 861-876.
3. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic literature review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634.
4. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, et al. Management of adult patients with idiopathic thrombocytopenic purpura after failure of splenectomy. A systematic review. Ann Int Med 2004; 140: 112-120.
5. Cheng Y, Wong RSM, Soo YOY, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. New Eng J Med 2003; 349: 831-836.
6. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patinets affected by idiopathic thormbocytopenic purpura: A GIMEMA experience. Blood 2007; 109: 1401-1407.
7. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107: 2639-2642.
8. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Int Med 2007; 146: 25-33.
9. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004.
10. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New Eng J Med 2007; 357: 2237-2347.
11. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomized controlled trial. Lancet 2008; 371: 395-403.
12. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomized, double-blind, placebo-controlled trial. Lancet 2009; 373: 641-648.
13. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-2171.
14. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard care in patients with immune thrombocytopenia. New Eng J Med 2010; 363: 1889-1899.
15. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomized, phase 3 study. Lancet 2011; 377: 393-402.
16. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115: 2755-2762.
17. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
18. Neunert CE, Lim W, Crowther MA, et al. The American Society of Hematology 2011 evidenced-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207.
19. Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytoenic purpura. Blood 2010; 115: 29-31.
20. Guidry JA, George JN, Vesely SK, et al. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: Patient and hematologist perspectives. Eur J Haematol 2009; 83: 175-182.
21. Guidry JA, Watson SP, George JN, et al. Addendum to corticosteroid side effects and risk for bleeding in immune thrombocytopenic purpura: Patient perspectives. Eur J Haematol 2009; 83: 497-498.
22. Shulman NR, Weinrach RS, Libre EP, Andrews HL. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. Trans Assoc Amer Phys 1965; 78: 374-390.
23. 111In-labeled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: A report from the United Kingdom ITP Registry. Br J Haematol 2010; 151: 477-487.
24. Cuker A, Cines DB. Evidence-based mini-review: Is Indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia? Hematology Am Soc Hematology Educ Program 2010; 385-386.
25. Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy. A population-based cohort study. Ann Int Med 2009; 151: 546-555.
26. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009; 114: 2861-2868.
27. Thomsen RW, Schoonen WM, Farkas DK, et al. Risk of venous thromboembolism in splenectomized patients compared with the general population and appendectomized patients: A 10-year nationwide cohort study. J Thromb Haemost 2010; 8: 1413-1416.
28. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
29. Guyett GH, Cook DJ, Jaeschke R, et al. Grades of recommendation for antithrombotic agents: American College of chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 123S-131S.